SeaStar Medical Secures ICD-10-PCS Codes for AKI Therapy, Streamlining Hospital Billing
Event summary
- SeaStar Medical's QUELIMMUNE therapy for Acute Kidney Injury (AKI) now has dedicated ICD-10-PCS codes effective October 1, 2026.
- New codes include 5A1D701, 5A1D801, and 5A1D901 for different durations of selective cytopheresis.
- Codes aim to simplify hospital billing, track clinical outcomes, and expand access to QUELIMMUNE therapy.
- QUELIMMUNE showed a 77% survival rate in clinical trials, reducing mortality by ~50% compared to historical data.
The big picture
The introduction of ICD-10-PCS codes for SeaStar Medical's QUELIMMUNE therapy marks a critical step in integrating the treatment into standard hospital workflows. This development aligns with broader trends in precision medicine, where targeted therapies for hyperinflammation are gaining traction. The codes not only facilitate billing but also position SeaStar Medical to expand its addressable market, particularly if the NEUTRALIZE-AKI trial succeeds in validating the therapy for adult AKI patients.
What we're watching
- Regulatory Expansion
- Whether the new codes will accelerate adoption of QUELIMMUNE in adult AKI patients pending approval.
- Clinical Validation
- The pace at which post-approval registry data confirms QUELIMMUNE's survival benefits in pediatric AKI.
- Market Penetration
- How the NEUTRALIZE-AKI trial results will impact SeaStar Medical's strategy for broader SCD therapy applications.
Related topics
